Advertisement

May 12, 2020

FDA Clears Transit Scientific's XO Cross Microcatheter Platform

May 12, 2020—Transit Scientific announced that the FDA cleared the XO Cross microcatheter platform for guidewire support, exchange, and contrast media injection in the peripheral vasculature. The 0.7–1.3-mm outer-diameter catheters are used to provide guidewire support, facilitate guidewire exchanges, access distal anatomy, cross lesions, deliver therapeutic embolics, inject contrast media, and/or perform other procedures during complex endovascular procedures.

Transit Scientific will launch the 2-F XO Cross 14 microcatheter, 2.6-F XO Cross 18 microcatheter, and the 3.8-F XO Cross 35 support catheter for use with standard 0.014-, 0.018-, and 0.035-inch guidewires in 90-, 135-, 150-, and 175-cm working lengths. The 175-cm versions are designed to support radial artery access to peripheral cases.

According to the company, the XO Cross microcatheter platform is designed to provide pushability, trackability, flexibility, and torque response to access challenging lesions. The nontapered metal-alloy and polymer construction deliver high fatigue-resistance against tough calcium and plaque found in late-stage peripheral artery disease and critical limb ischemia.

“We use multiple microcatheters every day,” commented George Adams, MD, an interventional cardiologist at UNC Rex Healthcare in Raleigh, North Carolina. “Improving access to distal vasculature is important. We are performing more radial procedures too and need long, responsive, and fatigue-resistant microcatheter technology.”

Richard Saxon, MD, added, “Tapered catheter designs with larger proximal shafts make it impossible to use as coaxial or tri-axial systems. The XO Cross nontapered design should dramatically reduce that problem and help us achieve success more quickly, even in the most difficult cases.” Dr. Saxon is an interventional radiologist at Tri-City Medical Center in Oceanside, California.

Advertisement


May 12, 2020

Micro Medical Solutions Begins Pivotal STAND Trial of MicroStent to Treat BTK Arterial Disease

May 12, 2020

Medtronic’s Valiant Captivia TEVAR Device to Treat Acute Complicated TBAD Evaluated at 5-Year Follow-Up